The global opioid use disorder market was valued at $196.2 million in 2021, and is projected to reach $385.8 million by 2031, registering a CAGR of 7.1% from 2022 to 2031. Opioid is a class of pain relievers that includes substances, which relax muscles and alleviate pain & stress. Prescription opioids are used to treat moderate-to-severe pain such as hydrocodone, oxycodone, codeine, fentanyl, methadone, morphine, and other pharmaceutical opioids. Opioid usage disorder (OUD) is a chronic, relapsing brain disorder that is characterized by obsessive opioid seeking and use despite negative effects. Opioids use disorder is regarded as brain disorder because it involves functional alterations to brain circuits involved in motivation, stress, self-control, and decision-making, and those changes may persist for a long period after drug use has stopped. Opioid use disorder consists of an overpowering desire to use opioids, increased opioid tolerance, and withdrawal syndrome when discontinued.
The opioids use disorder market is driven by increase in number of patients suffering from wide range of severe and chronic diseases such as cancer, cardiovascular disease, pain arising from injuries and other conditions. For instance, according to World Cancer Research Fund International, in 2020, around 18,094,716 new cancer cases diagnosed over the globe. As per the same source Breast and lung cancers were the most common cancers worldwide, 2,261,419 breast cancer and 2,206,771 lung cancer new cases diagnosed over the globe. Thus, rise in number of cancer cases cause increase in incidence of surgeries. Surge in number of surgical procedures cause rise in use of opioid drugs to relieve post-surgical pain. Therefore, this factor can cause addiction of opioid drugs in patients. Thus, this factor is anticipated to drive the growth of opioids use disorder market. Moreover, according to the Journal of JAMA Netw Open, in December 2021, around 5. 9 million population were reported to have undergone surgical procedure in the Rest of LAMEA In addition, according to Canadian Joint Replacement Registry (CJRR), approximately more than 75,000 knee replacement and 63,000 hip replacement surgeries were performed in the Canada from 2019 to 2020. As per the same source the knee and hip replacement surgery is the second most common surgery in Canada. This report also states 2.4% increase in the hip replacement surgery from 2019 to 2020.
In addition, increase in consideration of buprenorphine patches as an effective treatment mode to propel opioids use disorder market growth. The increase in use of buprenorphine patches as a successful treatment for opioid use disorder is one of the anticipated trends in the global market for treating opioid addiction. The use of buprenorphine patches is regarded as a cutting-edge strategy for treating opioid use disorder. Transdermal patches are a more pleasant drug delivery method that successfully lowers pain and can be self-administered by the patient than conventional therapy modalities such as injections. These buprenorphine patches can also serve as a potential substitute for people who need immediate treatment for opioid use disorder. In addition, governments globally have increased the expenditure on the healthcare sector. For instance, according to the Centers for Medicare & Medicaid Services, the U.S. health care spending grew by 9.7% from 2020 to 2019, reaching $4.1 trillion ($12,530 per person). Similarly, as per the Office for National Statistics, total healthcare expenditure in the UK accounted for 12.8% of the gross domestic product (GDP) in 2020, compared to 10.2% in 2019.
Furthermore, it has been estimated that approximately 30% of the healthcare expenditure is used in upgrading the healthcare infrastructure, especially medical equipment and medicine used at public health centers, such as hospitals. Hence, the rise in healthcare expenditure across the globe is expected to fuel the demand for opioids use disorder drugs application for treatment purpose, thereby boosting the growth of opioid use disorder market. On the other hand, side effects associated to opioids use disorder drugs are anticipated to restrain the growth of the opioids use disorder market.
The opioids use disorder market is segmented on the basis of type, age group, route of administration, distribution channel, and region. On the basis of type, the market is segmented into agonist and antagonist. The agonist segment further sub-categorized into methadone and buprenorphine. On the basis of age group, the market is classified into 19 to 39, 40 to 59 and age 60 and over. On the basis of route of administration, the market is classified into oral, intravenous and sublingual. On the basis of distribution channel, the market is divided into hospital pharmacy, retail pharmacy. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Some of the major companies that operate in the global opioids use disorder market include Alkermes, AstraZeneca Plc., BioDelivery Sciences International Inc., Braeburn, Camurus, Cerebral, Dr Reddy, Hikma Pharmaceuticals PLC, Indivior PLC, Mallinckrodt Pharmaceuticals, NYC Health + Hospitals, Orexo AB, Pear Therapeutics, Pfizer, Reckitt Benckiser Pharmaceuticals Inc., Sandoz (Novartis), Titan Pharmaceuticals, Inc., and Viatris Inc.
The opioids use disorder market is driven by increase in number of patients suffering from wide range of severe and chronic diseases such as cancer, cardiovascular disease, pain arising from injuries and other conditions. For instance, according to World Cancer Research Fund International, in 2020, around 18,094,716 new cancer cases diagnosed over the globe. As per the same source Breast and lung cancers were the most common cancers worldwide, 2,261,419 breast cancer and 2,206,771 lung cancer new cases diagnosed over the globe. Thus, rise in number of cancer cases cause increase in incidence of surgeries. Surge in number of surgical procedures cause rise in use of opioid drugs to relieve post-surgical pain. Therefore, this factor can cause addiction of opioid drugs in patients. Thus, this factor is anticipated to drive the growth of opioids use disorder market. Moreover, according to the Journal of JAMA Netw Open, in December 2021, around 5. 9 million population were reported to have undergone surgical procedure in the Rest of LAMEA In addition, according to Canadian Joint Replacement Registry (CJRR), approximately more than 75,000 knee replacement and 63,000 hip replacement surgeries were performed in the Canada from 2019 to 2020. As per the same source the knee and hip replacement surgery is the second most common surgery in Canada. This report also states 2.4% increase in the hip replacement surgery from 2019 to 2020.
In addition, increase in consideration of buprenorphine patches as an effective treatment mode to propel opioids use disorder market growth. The increase in use of buprenorphine patches as a successful treatment for opioid use disorder is one of the anticipated trends in the global market for treating opioid addiction. The use of buprenorphine patches is regarded as a cutting-edge strategy for treating opioid use disorder. Transdermal patches are a more pleasant drug delivery method that successfully lowers pain and can be self-administered by the patient than conventional therapy modalities such as injections. These buprenorphine patches can also serve as a potential substitute for people who need immediate treatment for opioid use disorder. In addition, governments globally have increased the expenditure on the healthcare sector. For instance, according to the Centers for Medicare & Medicaid Services, the U.S. health care spending grew by 9.7% from 2020 to 2019, reaching $4.1 trillion ($12,530 per person). Similarly, as per the Office for National Statistics, total healthcare expenditure in the UK accounted for 12.8% of the gross domestic product (GDP) in 2020, compared to 10.2% in 2019.
Furthermore, it has been estimated that approximately 30% of the healthcare expenditure is used in upgrading the healthcare infrastructure, especially medical equipment and medicine used at public health centers, such as hospitals. Hence, the rise in healthcare expenditure across the globe is expected to fuel the demand for opioids use disorder drugs application for treatment purpose, thereby boosting the growth of opioid use disorder market. On the other hand, side effects associated to opioids use disorder drugs are anticipated to restrain the growth of the opioids use disorder market.
The opioids use disorder market is segmented on the basis of type, age group, route of administration, distribution channel, and region. On the basis of type, the market is segmented into agonist and antagonist. The agonist segment further sub-categorized into methadone and buprenorphine. On the basis of age group, the market is classified into 19 to 39, 40 to 59 and age 60 and over. On the basis of route of administration, the market is classified into oral, intravenous and sublingual. On the basis of distribution channel, the market is divided into hospital pharmacy, retail pharmacy. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Some of the major companies that operate in the global opioids use disorder market include Alkermes, AstraZeneca Plc., BioDelivery Sciences International Inc., Braeburn, Camurus, Cerebral, Dr Reddy, Hikma Pharmaceuticals PLC, Indivior PLC, Mallinckrodt Pharmaceuticals, NYC Health + Hospitals, Orexo AB, Pear Therapeutics, Pfizer, Reckitt Benckiser Pharmaceuticals Inc., Sandoz (Novartis), Titan Pharmaceuticals, Inc., and Viatris Inc.
KEY BENEFITS FOR STAKEHOLDERS
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the opioid use disorder market analysis from 2021 to 2031 to identify the prevailing opioid use disorder market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the opioid use disorder market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global opioid use disorder market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Drug Type
- Agonist
- Type
- Methadone
- Buprenorphine
- Antagonist
By Age group
- 19 to 39
- 40 to 59
- Age 60 and over
By Route of Administration
- Oral
- Intravenous
- Sublingual
By Distribution channal
- Hospital pharmacy
- Retail Pharmacy
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Alkermes, Inc.
- AstraZeneca plc
- BioDelivery Sciences International Inc.
- braeburn pharmaceuticals
- Camurus
- Dr Reddy Laboratories Ltd
- Pear Therapeutics
- Hikma Pharmaceuticals PLC
- mallinckrodt pharmaceuticals
- NYC Health Hospitals
- Orexo AB
- OREXO AB
- Indivior PLC
- Reckitt Benckiser Pharmaceuticals Inc
- Sandoz
- Titan Pharmaceuticals, Inc.
- Viatris Inc
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: OPIOID USE DISORDER MARKET, BY DRUG TYPE
CHAPTER 5: OPIOID USE DISORDER MARKET, BY AGE GROUP
CHAPTER 6: OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION
CHAPTER 7: OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNAL
CHAPTER 8: OPIOID USE DISORDER MARKET, BY REGION
CHAPTER 9: COMPANY LANDSCAPE
CHAPTER 10: COMPANY PROFILES
List of Tables
List of Figures
Executive Summary
According to the report, titled, “Opioid Use Disorder Market," the opioid use disorder market size was valued at $2.8 billion in 2021, and is estimated to reach $8.1 billion by 2031, growing at a CAGR of 11.5% from 2022 to 2031. Opioids are produced synthetically or naturally in laboratories to mimic the chemical features of opioids that interact with opioid receptors on nerve cells in the body and brain to alleviate pain. They are a group of substances that also includes heroin, synthetic opioids, and prescription painkillers. Prescription opioids are intended to be used to manage acute pain, such as that experienced after an injury or surgery, chronic pain, cancer that is actively being treated, palliative care, and end-of-life care. Many patients who are being treated by a doctor rely on prescribed opioids to help them manage their problems. Opioid use disorder is a chronic, lifelong condition with grave potential outcomes, such as disability, relapses, and death.Factors that drive the opioid use disorder market growth include increase in cases of opioid addiction, and rise in number of opioid industry. Rise in numbers of people are afflicted with a variety of severe and chronic diseases, including cancer, cardiovascular disease, pain from injuries, and other illnesses. Chronic pain is a common side effect of many disorders, which is frequently treated with opioid medicines. The patient is more likely to develop a drug addiction even while the discomfort is reduced. Withdrawal symptoms could develop in the patient as a result of the increasing dependence and sudden termination of the medications. In addition, the healthcare industry in emerging economies is developing at a significant rate, owing to surge in demand for better healthcare services and significant rise in research & development activities for opioids in treatment of chronic pain. For instance, according to the National Center of Biotechnology Information (NCBI), it was estimated that around five billion people suffered from chronic pain in 2021.
Moreover, according to Centre for Disease Control and Prevention, in 2019, it was reported that opioids were involved in 49,860 overdose death in U.S. In addition, according to the National Institute of Drug Abuse, more than 130 people in the U.S. die daily due to overdosing of opioids. Thus, rise in cases of opioid addiction anticipated to fuel the growth of opioid use disorder market. Moreover, rise in product launch and product approval for opioid use disorder drugs anticipated to fuel the growth of market. For instance, in May 2020, Indivior PLC, a pharmaceutical company, announced the approval of Subutex from Swedish Medical Products Agency (MPA). Subutex prolonged release solution for injection, 100 and 300mg for substitution treatment of opioid dependence in adults and adolescents over 16 years of age. Moreover, in February 2019, Dr. Reddy's Laboratories, a pharmaceutical company, announced the re-launch of buprenorphine and Naloxone Sublingual Film, 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg, a therapeutic equivalent generic version of Suboxone sublingual film, in the United States market. Buprenorphine is agonist type of opioids use disorders drug.
Moreover, rise in number of surgical procedures, chronic cardiovascular diseases, cancer is anticipated to fuel the opioid use disorder market trends. Increase in number of surgical procedures cause rise in the use of opioid for pain management after surgery. It causes rise in prevalence of addition to opioids which is anticipated to cause opioids use disorder. Thus, this factor is anticipated to fuel the market growth. Moreover, increase in the prevalence of chronic diseases, cardiovascular diseases, and cancer lead to increase in the number of surgeries associated with post-surgical pain. Therefore, this factor fuels the market growth. For instance, according to the Centers for disease control and prevention (CDC) approximately 659,000 population in the U.S. experienced death from heart disease each year. According to the same report in 2019, a total of 360,900 people died due to coronary heart disease.
Every year in the U.S. approximately 805,000 population are diagnosed with heart attack among which 605,000 experienced their first heart attack. This factor upsurges the need for heart surgery, which further increases the need for opioids to relive post-surgical pain. Thus, this factor drives the growth of the opioids use disorder market.
On the basis of type, the opioid use disorder market share is segmented into agonist and antagonist. The agonist segment dominated the market in 2021, and is expected to remain dominant during the forecast period, owing to rise in the prevalence of chronic pain, high prevalence of opioid abuse and rising geriatric population prone to painful disease.
On the basis of age group, the market is classified into 19 to 39, 40 to 59 and age 60 and over. The 19 to 39 segment dominated the market in 2021, and is expected to remain dominant during the forecast period, owing to rise in the prevalence of chronic diseases such as cancer, cardiovascular diseases and orthopedic diseases associated with chronic pain.
On the basis of route of administration, the market is classified into oral, intravenous and sublingual. The intravenous dominated the market in 2021, and is expected to remain dominant during the forecast period, owing to buprenorphine is agonist type of opioids use disorder drug which is used by sublingual route for administration purpose, rise in the demand of buprenorphine for the treatment of opioids use disorder treatment.
On the basis of distribution channel, the market is divided into hospital pharmacy and retail pharmacy. The hospitals segment dominated the market in 2021, and is expected to remain dominant during the forecast period, owing to rise in number of hospital pharmacies, increase in expenditure by government to develop healthcare infrastructure and increase in the prevalence of opioids use disorder.
The North America market was dominant, in terms of revenue among other regions in 2021, owing to increase the number of product launch, and product approval for opioids use disorder, increase in the prevalence of chronic diseases such as cancer, cardiac diseases and orthopedic diseases and well-established healthcare infrastructure in North America. On the other hand, Asia-Pacific was the second-largest contributor in the market in 2021, and is expected to register fastest CAGR during the forecast period, owing rise in the geriatric populations, rise in the awareness regarding availability of healthcare services and increase in the number of chronic diseases.
Key Findings of the Study
- By type, the agonist segment was the highest contributor to the market in 2021.
- By age group, the 19 to 39 segment was the highest contributor to the market in 2021.
- By route of administration, the intravenous segment dominated the market in 2021, and is expected to continue this trend during the forecast period.
- By distribution channel, the hospital pharmacy segment dominated the market in 2021, and is expected to continue this trend during the forecast period.
- By region, North America garnered the largest revenue share in 2021, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.
Companies Mentioned
- Alkermes, Inc.
- Astrazeneca plc
- Biodelivery Sciences International Inc.
- Braeburn Pharmaceuticals
- Camurus
- Dr Reddy Laboratories Ltd
- Pear Therapeutics
- Hikma Pharmaceuticals plc,
- Mallinckrodt Pharmaceuticals
- Nyc Health Hospitals
- Orexo Ab
- Orexo Ab
- Indivior plc
- Reckitt Benckiser Pharmaceuticals Inc
- Sandoz
- Titan Pharmaceuticals, Inc.
- Viatris Inc
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 324 |
| Published | August 2022 |
| Forecast Period | 2021 - 2031 |
| Estimated Market Value ( USD | $ 196.2 million |
| Forecasted Market Value ( USD | $ 385.8 million |
| Compound Annual Growth Rate | 7.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 17 |
